Rho-associated Kinase Inhibitors for the Treatment of Ocular Diseases

Journal Title: Ophthalmology and Vision Science - Year 2016, Vol 1, Issue 1

Abstract

The Rho family consists of a series of small G-proteins, including RhoA, RhoB, and RhoC. When bounded to guanosine triphosphate, Rho molecules activate their effectormolecule,Rho-associated kinase (ROCK). A Rho-ROCK signal is a regulator of factors such calciumindependent smooth muscle contraction, cell adhesion and motility, as well as of actin cytoskeleton [1]. In September 2014, a ROCK inhibitor, ripasudil,was approved in Japan for the treatment of glaucoma and ocular hypertension as the first anti-glaucoma agent of this category in the world.In this Editorial, I describe the unique mechanisms by which ROCK inhibitors lower intraocular pressure (IOP), as well as their other actions. It was found in Japan that several kinds of ROCK inhibitors, including Y-27632 and HA1077 (fasudil), reduce IOP by increasing conventional outflow through the Schlemm canal. Honjo., et al. Reported that administration of the ROCK inhibitors caused a reduction in IOP and an increase in the outflow facility in rabbits. Their in vitro experiments suggested that the IOP-lowering effects of the ROCK inhibitors might be related to the altered cellular behavior of trabecular meshwork cells and relaxation of ciliary muscle contraction [2,3]. Ripasudil, a selective ROCK inhibitor, has recently been approved for human use after undergoing a series of clinical trials, and was found to have additive effect when combined with timolol or latanoprost [4-6]. It is noteworthy that ripasudil is now the only anti-glaucoma agent in clinical use that lowers IOP by modulating the conventional aqueous outflow pathway [7].

Authors and Affiliations

Tetsuya Sugiyama

Keywords

Related Articles

Prevalence and surgical outcome of congenital lacrimal fistulas in Guatemala

Background: The purpose of this study was to review the prevalence, surgical techniques and outcome of congenital lacrimal fistulas performed over a 10-year period in Rodolfo Robles hospital, in Guatemala. Method: The me...

Problem in Diagnosis and Treatment of Vogt Koyanagi- Harada's Disease in African Black People: One Clinical Observation in Abidjan

Introduction: Vogt-Koyanagi- Harada syndrome is a severe uveitis associated with extraocular manifestations, rare in African melanoderm. We report a clinical case focusing on the diagnostic difficulties and the evolution...

The Curious Case of an "Unorthodox" Xen45 Implant

The new MIGS alternatives available on the market today, are continuously proving to be a very reliable tools to managing many cases throughout the spectrum of the many manifestations of glaucoma. Furthermore, when combi...

An Unusual Cause of Optic Atrophy in Childhood

Purpose: To report a rare and interesting cause of bilateral optic atrophy secondary to hemolytic uremic syndrome (HUS). Case Report: A 6-year-old asymptomatic child was referred with bilateral pale optic discs. She was...

Rho-associated Kinase Inhibitors for the Treatment of Ocular Diseases

The Rho family consists of a series of small G-proteins, including RhoA, RhoB, and RhoC. When bounded to guanosine triphosphate, Rho molecules activate their effectormolecule,Rho-associated kinase (ROCK). A Rho-ROCK sign...

Download PDF file
  • EP ID EP259464
  • DOI -
  • Views 116
  • Downloads 0

How To Cite

Tetsuya Sugiyama (2016). Rho-associated Kinase Inhibitors for the Treatment of Ocular Diseases. Ophthalmology and Vision Science, 1(1), 1-3. https://europub.co.uk/articles/-A-259464